Morgan Stanley Has Lowered Expectations for Danaher (NYSE:DHR) Stock Price

Danaher (NYSE:DHR) had its price target reduced by stock analysts at Morgan Stanley from $270.00 to $255.00 in a report released on Wednesday,MarketScreener reports. Morgan Stanley’s price objective points to a potential upside of 40.73% from the company’s previous close.

A number of other research analysts have also recently weighed in on DHR. KeyCorp reiterated an “overweight” rating on shares of Danaher in a report on Thursday, January 29th. The Goldman Sachs Group dropped their price target on Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a research note on Monday, April 13th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Danaher in a research note on Thursday, January 29th. Barclays cut their price target on shares of Danaher from $250.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. Finally, Argus set a $265.00 price target on shares of Danaher in a research report on Wednesday, January 14th. Seventeen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $242.45.

Danaher Price Performance

DHR opened at $181.20 on Wednesday. Danaher has a 1 year low of $180.03 and a 1 year high of $242.80. The company’s 50 day simple moving average is $197.17 and its 200 day simple moving average is $214.35. The stock has a market capitalization of $128.23 billion, a PE ratio of 35.05, a P/E/G ratio of 2.64 and a beta of 0.95. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.51 and a current ratio of 1.87.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.96%. The company had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $6 billion. During the same quarter last year, the firm posted $1.88 earnings per share. Danaher’s revenue was up 3.7% on a year-over-year basis. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. As a group, sell-side analysts expect that Danaher will post 8.39 EPS for the current year.

Insider Activity at Danaher

In related news, EVP Gregory M. Milosevich sold 1,320 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $208.01, for a total transaction of $274,573.20. Following the transaction, the executive vice president directly owned 5,099 shares of the company’s stock, valued at approximately $1,060,642.99. The trade was a 20.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 10.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in DHR. Tyche Wealth Partners LLC bought a new position in Danaher during the 3rd quarter valued at $462,000. Bank Pictet & Cie Europe AG raised its stake in shares of Danaher by 25.4% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 366,481 shares of the conglomerate’s stock valued at $83,895,000 after purchasing an additional 74,301 shares in the last quarter. Lockheed Martin Investment Management Co. raised its stake in shares of Danaher by 49.4% in the 3rd quarter. Lockheed Martin Investment Management Co. now owns 25,340 shares of the conglomerate’s stock valued at $5,024,000 after purchasing an additional 8,380 shares in the last quarter. Johnson Investment Counsel Inc. lifted its position in shares of Danaher by 2.9% during the third quarter. Johnson Investment Counsel Inc. now owns 664,705 shares of the conglomerate’s stock worth $131,784,000 after purchasing an additional 18,744 shares during the last quarter. Finally, Resona Asset Management Co. Ltd. grew its stake in Danaher by 4.6% in the third quarter. Resona Asset Management Co. Ltd. now owns 513,288 shares of the conglomerate’s stock worth $100,071,000 after purchasing an additional 22,595 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q1 EPS beat and slight full?year EPS raise: Danaher reported $2.06 non?GAAP EPS (ahead of estimates) and nudged FY?2026 adjusted EPS guidance to a range that was only modestly higher, supporting the view of durable profitability. Read More.
• Positive Sentiment: Analyst support from Evercore: Evercore raised its price target (to $232) and maintained an outperform stance, providing some buy?side reinforcement amid the downdraft. Read More.
• Neutral Sentiment: Large euro?note offering announced: Danaher priced ~€3.0B net of proceeds in four tranches (2028–2038 maturities). The deal boosts liquidity but increases gross debt on the balance sheet while funding corporate needs (including M&A). Read More.
• Neutral Sentiment: Bioprocessing strength vs. mixed start: Management highlighted bioprocessing momentum and acquisition strategy, which helped headline growth, but the quarter showed mixed signals across segments. Read More.
• Negative Sentiment: Revenue miss and Diagnostics softness: Revenue rose ~3.7% Y/Y but missed consensus; core revenue growth was modest and Diagnostics saw weakness (lighter respiratory season at Cepheid), which worried investors despite the EPS beat. Read More.
• Negative Sentiment: Multiple price?target cuts: Several firms trimmed targets (JPMorgan, UBS, Guggenheim, Wells Fargo, TD Cowen among others), which can prompt headline selling and reduce near?term upside expectations. Read More. Read More. Read More.
• Negative Sentiment: Market concern about Masimo deal & capital allocation: Commentators flagged near?term uncertainty around integration, capital allocation and how incremental spending/financing (including the euro notes) will affect returns, adding to investor caution. Read More.
• Negative Sentiment: Insider selling & repositioning by institutions: Reports of recent insider sales and large institutional rebalancing were cited in market coverage, which may have amplified downward pressure. Read More.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.